Nanobiotix (NBTX): A Speculative Long on a Potential Nano-Radiotherapy Platform
Nanobiotix is a late-clinical stage French biotech developing NanoXray radioenhancers (NBTXR3 / JNJ-1900) and a separate Nanoprimer platform. Recent Phase 2 lung data and a €85m/ ~$100m follow-on that closed in May 2026 give the company runway into 2029. At a $1.72B market cap and current ADS price near $34.04, the stock offers asymmetric upside if…